» Articles » PMID: 7923049

Molecular Adjuvants and Immunomodulators: New Approaches to Immunization

Overview
Specialty Microbiology
Date 1994 Jul 1
PMID 7923049
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Epitopes on microbial antigens responsible for protective immunity have begun to be identified and isolated, and their chemical structures have been determined. Ensuing knowledge of their weak immunizing capacity per se has led to an appreciation of the need for adjuvants to increase the immunogenicity of these low-molecular-weight synthetic structures. As such, a recent surge in adjuvant research has emerged. Accordingly, this review will highlight a number of those adjuvant substances whose activity in animals indicates a potential use in human vaccines. In addition, the potential of several well-defined substances, termed immunomodulators, which nonspecifically stimulate resistance of animals to multiple 50% lethal doses of microbial challenge is described. Among the most extensively characterized adjuvants of microbial origin discussed in detail are (i) the lipopolysaccharides isolated from gram-negative bacteria and their nontoxic analogs, (ii) the synthetic muramyl dipeptides and their multiple analogs, and (iii) the synthetic polyribonucleotide complexes, mimicking the interferon-inducing capacity of viruses. Discussed also are the heat-labile enterotoxin of Escherichia coli, the nonionic block copolymers, the saponins, a quinolamine derivative, and the hormone dihydroepiandrosterone.

Citing Articles

Advances in Infectious Disease Vaccine Adjuvants.

Fan J, Jin S, Gilmartin L, Toth I, Hussein W, Stephenson R Vaccines (Basel). 2022; 10(7).

PMID: 35891284 PMC: 9316175. DOI: 10.3390/vaccines10071120.


Investigating the Efficiency of Recombinant FliC-Loaded Spores in Mice Immunization against Serovar Typhi.

Ghorbani N, Assmar M, Amirmozafari N, Issazadeh K Iran J Public Health. 2021; 50(7):1474-1482.

PMID: 34568187 PMC: 8426781. DOI: 10.18502/ijph.v50i7.6638.


Mucosal Vaccination via the Respiratory Tract.

Hellfritzsch M, Scherliess R Pharmaceutics. 2019; 11(8).

PMID: 31374959 PMC: 6723941. DOI: 10.3390/pharmaceutics11080375.


Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant.

Hildebrand D, Metz-Zumaran C, Jaschkowitz G, Heeg K Front Immunol. 2019; 10:1279.

PMID: 31214204 PMC: 6558036. DOI: 10.3389/fimmu.2019.01279.


Toll-like receptors in immunity and inflammatory diseases: Past, present, and future.

Vijay K Int Immunopharmacol. 2018; 59:391-412.

PMID: 29730580 PMC: 7106078. DOI: 10.1016/j.intimp.2018.03.002.


References
1.
Takada H, Kotani S, Tsujimoto M, Ogawa T, Takahashi I, Harada K . Immunopharmacological activities of a synthetic counterpart of a biosynthetic lipid A precursor molecule and of its analogs. Infect Immun. 1985; 48(1):219-27. PMC: 261938. DOI: 10.1128/iai.48.1.219-227.1985. View

2.
Bernstein D, Miller R, Harrison C . Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs. J Infect Dis. 1993; 167(3):731-5. DOI: 10.1093/infdis/167.3.731. View

3.
Morrison D, Ryan J . Bacterial endotoxins and host immune responses. Adv Immunol. 1979; 28:293-450. DOI: 10.1016/s0065-2776(08)60802-0. View

4.
Loppnow H, Brade H, Durrbaum I, Dinarello C, Kusumoto S, Rietschel E . IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol. 1989; 142(9):3229-38. View

5.
Allison A, Byars N . Adjuvant formulations and their mode of action. Semin Immunol. 1990; 2(5):369-74. View